Cryopyrin-Associated Periodic Syndromes (CAPS)

One spectrum, several names

Cryopyrin-associated periodic syndromes are associated with changes in NLRP3. Older names describe parts of the spectrum: familial cold autoinflammatory syndrome (FCAS), Muckle–Wells syndrome, and neonatal-onset multisystem inflammatory disease (NOMID), also called CINCA. These labels overlap rather than forming perfectly separate boxes.

Symptoms often begin early in life and may include a hive-like rash, fever, joint symptoms and red eyes. Cold can trigger some episodes, but it is not a trigger for everyone. Some people have ongoing symptoms rather than distinct attacks.

Why evaluation matters

Depending on the form, CAPS can affect hearing, the eyes, the nervous system and other organs. A clinician assesses the full history and examination, inflammatory tests and genetic findings. Some disease-causing changes are present in only a proportion of cells—called mosaicism—so the testing method can matter.

Treatment and monitoring

Medicines that block interleukin-1 (IL-1), an inflammatory signal, are central to CAPS care. The choice and schedule depend on the person’s disease and circumstances. Treatment aims to control symptoms and inflammation and prevent organ damage.

Follow-up may include hearing and eye assessments, kidney and inflammatory tests, and other checks based on the person’s symptoms. Feeling better is important, but it does not replace the monitoring plan.

Preparing for care

• Which name best describes my condition, and does that change my monitoring?
• Should hearing, vision or neurologic symptoms be assessed?
• What does my genetic result mean for me and my family?
• What should I do if symptoms return before the next dose?

Record the timing of symptoms and possible triggers. Bring photographs of intermittent rashes through your clinic’s secure communication system. New vision changes, severe headache with concerning symptoms, or breathing difficulty need prompt assessment.